Communiqué de presse
GlycoNet and partners invest $7.7 million in Canadian health innovation
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
GlycoNet researcher receives Scientific Achievement and Innovation Award
Dr. Ratmir Derda’s achievements were recently recognized with an award at BioAlberta’s 2021 Awards Gala.
More stories
- Tout
- Prix
- Communauté
- Profil du Réseau
- Communiqué de presse
- Points saillants de la recherche
GlycoNet investigator presents game-changing glycomics research to the Parliamentary Health Research Caucus
Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.
New research reveals clues to how antibodies get fine-tuned to fight infection
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
New educational resources bolster vaccine confidence, information literacy
GlycoNet received a NSERC PromoScience grant and partnered with the Centre for Mathematics, Science and Technology Education to develop resources that educators can use to teach the science behind vaccines and engage students in critical thinking.
New treatment could reduce tissue damage in Duchenne muscular dystrophy patients by as much as 50 per cent
A carbohydrate-derived drug shows promise as a treatment to slow progression of the most common form of muscular dystrophy.
Op-ed: Glycomics is the new frontier in bioinnovation
Read about the future of glycomics in this op ed by GlycoNet board chair Karimah Es Sabar, republished from the Hill Times. Canada has a tremendous opportunity with continued investment in glycomics to establish global leadership and economic prosperity while at the same time solving some of the world’s most pressing challenges in health and environmental sustainability.
Glycomics: The New Frontier in Bioinnovation
In our new report: Why glycomics, the study of sugars on cells, is at the centre of a new surge of scientific and industry interest.
Making strides in Alzheimer’s research
GlycoNet researchers have made exciting advances in understanding Alzheimer’s disease and are developing a potential therapeutic strategy.
Top 10 stories from GlycoNet in 2021
A year in review in glycomics innovations.
Enzymes in bacteria found to have an unexpected taste for carbs
GlycoNet researchers studying complex enzymes gain insight into how some pathogens could potentially be targeted without antibiotics.
Réseau Canadien de la Glycomique
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tél.: 780-492-6204
Téléc.: 780-492-4147
Subscribe to GlycoNet’s Newsletter
© Réseau Canadien de la Glycomique (GlycoNet). Tous droits réservés.
French 
English